A Phase 3 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sanofi. Completed at 389 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 11 in phase 3, and was the 4th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2015.
This study's enrollment of 1,902 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2015, is one of 16 in phase 3, and was the 13th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma.
Secondary Objectives:
The total duration of study period for each participant is 67 to 69 weeks, including a screening period of 3 to 5 weeks, treatment period of 52 weeks, and post-treatment follow-up period of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Adults and adolescent participants with a physician diagnosis of asthma for ≥12 months, based on the Global Initiative for Asthma (GINA) 2014 Guidelines and the following criteria:
a) Existing treatment with medium to high dose ICS (≥250 mcg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or equivalent) in combination with a second controller (eg, long-acting beta agonist, leukotriene receptor antagonist) for at least 3 months with a stable dose ≥1 month prior to Visit 1.
i) Note for Japan: for participants aged 18 years and older, ICS must be on ≥200 mcg of fluticasone propionate twice daily or equivalent; for participants aged 12 to 17 years, ICS must be ≥100 mcg of fluticasone propionate twice daily or equivalent).
ii) Participants requiring a third controller for their asthma will be considered eligible for this study, and it should also be used for at least 3 months with a stable dose ≥1 month prior to Visit 1.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Drug: Placebo · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol
2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Drug: Dupilumab · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol
2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Drug: Placebo · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Drug: Dupilumab · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Also known as: SAR231893, REGN668
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
Drug page: Albuterol
Oral inhalation as needed
Drug page: Levalbuterol
Oral inhalation as needed
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 52
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time frame: Baseline, Week 24
Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time frame: Baseline, Week 24
Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time frame: Baseline, Week 24
Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Week 12
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Weeks 2, 4, 8, 24, 36, and 52
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Weeks 2, 4, 8, 24, 36, and 52
Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population
LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: Baseline to Week 52
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.
Time frame: Baseline up to Week 52
Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.
Time frame: Baseline up to Week 52
Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time frame: Baseline, Weeks 2, 4, 8, 12, 36, and 52
Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time frame: Baseline, Weeks 12, 36, and 52
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population
EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).
Time frame: Baseline, Weeks 12, 24, 36, and 52
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population
The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.
Time frame: Baseline, Weeks 12, 24, 36, and 52
Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis
The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
Time frame: Baseline, Weeks 12, 24, 36, and 52
Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis
RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).
Time frame: Baseline, Weeks 12, 24, 36, and 52
4148 participants were screened from Apr 2015-Sep 2016. 1902 were randomized at 321 centers/22 countries. 2246 were screen failures. 1897 participants were treated; some received a different treatment than that assigned at randomization and for adverse event (AE) analysis were allocated to treatment actually received (see footnotes in below table)
| Milestone | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Started | 317 | 631 | 321 | 633 |
| Treated | 315 | 629 | 321 | 632 |
| Completed | 295 | 586 | 301 | 582 |
| Not completed | 22 | 45 | 20 | 51 |
| Withdrew: Adverse event | 9 | 7 | 1 | 12 |
| Withdrew: Poor compliance to protocol | 1 | 1 | 2 | 2 |
| Withdrew: Other than specified above | 12 | 37 | 17 | 37 |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| Exacerbation per participant-year | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population | 0.871 (0.724 to 1.048) | 0.456 (0.389 to 0.534) | 0.970 (0.810 to 1.160) | 0.524 (0.450 to 0.611) |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Baseline | 1.76 ± 0.61 | 1.78 ± 0.62 | 1.75 ± 0.57 | 1.78 ± 0.60 |
| Week 12 | 1.92 ± 0.70 | 2.07 ± 0.76 | 1.93 ± 0.68 | 2.09 ± 0.70 |
| Change at Week 12 | 0.15 ± 0.36 | 0.28 ± 0.45 | 0.18 ± 0.39 | 0.31 ± 0.43 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent change | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population | 10.16 ± 23.88 | 18.74 ± 30.86 | 11.87 ± 26.40 | 20.89 ± 34.14 |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| Exacerbation per participant-year | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L | 1.007 (0.814 to 1.245) | 0.445 (0.368 to 0.538) | 1.081 (0.879 to 1.329) | 0.434 (0.359 to 0.525) |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Baseline | 1.77 ± 0.63 | 1.81 ± 0.63 | 1.75 ± 0.55 | 1.79 ± 0.59 |
| Change at Week 12 | 0.17 ± 0.36 | 0.34 ± 0.46 | 0.21 ± 0.38 | 0.35 ± 0.45 |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| Exacerbation per participant-year | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L | 1.081 (0.846 to 1.382) | 0.370 (0.289 to 0.475) | 1.236 (0.972 to 1.571) | 0.403 (0.317 to 0.512) |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Baseline | 1.78 ± 0.66 | 1.81 ± 0.64 | 1.73 ± 0.54 | 1.75 ± 0.59 |
| Change at Week 12 | 0.19 ± 0.39 | 0.39 ± 0.45 | 0.20 ± 0.40 | 0.43 ± 0.43 |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| Exacerbation per participant-year | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L | 0.675 (0.515 to 0.884) | 0.512 (0.418 to 0.628) | 0.732 (0.562 to 0.954) | 0.610 (0.502 to 0.742) |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| Exacerbation per participant-year | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline | 1.040 (0.824 to 1.314) | 0.560 (0.455 to 0.690) | 1.038 (0.818 to 1.317) | 0.639 (0.523 to 0.780) |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline | 0.14 ± 0.34 | 0.27 ± 0.42 | 0.20 ± 0.40 | 0.32 ± 0.43 |
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Baseline | 4.26 ± 1.02 | 4.31 ± 1.08 | 4.30 ± 1.03 | 4.28 ± 1.05 |
| Week 24 | 5.23 ± 1.07 | 5.46 ± 1.12 | 5.30 ± 1.15 | 5.47 ± 1.09 |
| Change at Week 24 | 0.95 ± 1.03 | 1.13 ± 1.14 | 1.02 ± 1.10 | 1.17 ± 1.11 |
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Baseline | 4.24 ± 0.98 | 4.24 ± 1.11 | 4.21 ± 0.97 | 4.36 ± 1.05 |
| Change at Week 24 | 0.97 ± 1.01 | 1.39 ± 1.15 | 1.02 ± 1.25 | 1.30 ± 1.15 |
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Baseline | 2.71 ± 0.73 | 2.76 ± 0.80 | 2.77 ± 0.77 | 2.77 ± 0.76 |
| Week 24 | 1.67 ± 1.06 | 1.33 ± 1.05 | 1.58 ± 1.08 | 1.37 ± 1.10 |
| Change at Week 24 | -1.06 ± 1.01 | -1.43 ± 1.05 | -1.19 ± 1.10 | -1.38 ± 1.10 |
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.
| Exacerbation per participant-year | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population | 0.081 (0.049 to 0.135) | 0.043 (0.027 to 0.068) | 0.034 (0.017 to 0.066) | 0.025 (0.014 to 0.043) |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L | 0.12 ± 0.32 | 0.21 ± 0.43 | 0.17 ± 0.39 | 0.21 ± 0.41 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent change | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L | 13.40 ± 27.01 | 26.41 ± 33.69 | 13.05 ± 25.27 | 30.58 ± 38.22 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent change | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline | 8.47 ± 20.94 | 17.99 ± 28.43 | 13.22 ± 26.52 | 23.41 ± 37.26 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent change | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L | 11.43 ± 24.71 | 22.04 ± 31.96 | 13.49 ± 25.18 | 24.04 ± 35.71 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | 0.08 ± 0.35 | 0.22 ± 0.38 | 0.10 ± 0.34 | 0.25 ± 0.40 |
| Change at Week 4 | 0.13 ± 0.35 | 0.24 ± 0.40 | 0.13 ± 0.34 | 0.27 ± 0.41 |
| Change at Week 8 | 0.15 ± 0.38 | 0.28 ± 0.42 | 0.19 ± 0.40 | 0.29 ± 0.43 |
| Change at Week 24 | 0.13 ± 0.40 | 0.31 ± 0.45 | 0.19 ± 0.44 | 0.30 ± 0.44 |
| Change at Week 36 | 0.14 ± 0.41 | 0.31 ± 0.48 | 0.21 ± 0.42 | 0.32 ± 0.45 |
| Change at Week 52 | 0.12 ± 0.38 | 0.31 ± 0.50 | 0.20 ± 0.42 | 0.32 ± 0.44 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent change | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | 5.78 ± 23.36 | 14.32 ± 26.55 | 6.60 ± 21.84 | 17.38 ± 30.82 |
| Change at Week 4 | 9.61 ± 25.54 | 16.11 ± 28.12 | 8.67 ± 23.55 | 18.77 ± 32.73 |
| Change at Week 8 | 10.27 ± 25.60 | 18.81 ± 29.80 | 12.24 ± 25.78 | 19.85 ± 33.63 |
| Change at Week 24 | 9.42 ± 26.76 | 19.76 ± 30.64 | 12.86 ± 28.14 | 20.75 ± 35.35 |
| Change at Week 36 | 10.57 ± 26.41 | 19.92 ± 32.26 | 13.45 ± 27.69 | 22.08 ± 35.93 |
| Change at Week 52 | 8.37 ± 23.59 | 19.96 ± 33.35 | 12.89 ± 27.70 | 21.57 ± 34.08 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| percent predicted of FEV1 | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | 2.58 ± 11.36 | 7.10 ± 12.28 | 3.32 ± 10.98 | 8.44 ± 13.20 |
| Change at Week 4 | 4.55 ± 11.69 | 7.92 ± 12.81 | 4.13 ± 11.41 | 9.20 ± 14.10 |
| Change at Week 8 | 4.93 ± 12.30 | 9.27 ± 13.13 | 6.08 ± 12.55 | 9.70 ± 14.15 |
| Change at Week 12 | 5.02 ± 12.10 | 9.22 ± 13.87 | 5.90 ± 13.02 | 10.28 ± 14.44 |
| Change at Week 24 | 4.38 ± 12.85 | 9.98 ± 13.94 | 6.41 ± 14.02 | 10.14 ± 14.75 |
| Change at Week 36 | 5.09 ± 12.99 | 10.12 ± 14.61 | 6.82 ± 13.54 | 10.94 ± 15.06 |
| Change at Week 52 | 4.25 ± 12.06 | 10.08 ± 14.79 | 6.68 ± 13.56 | 11.02 ± 14.59 |
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.
| liters/min | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| AM: Change at Week 2 | 4.19 ± 31.30 | 15.21 ± 39.45 | 3.45 ± 28.95 | 14.46 ± 36.29 |
| AM: Change at Week 4 | 6.23 ± 42.42 | 21.81 ± 53.85 | 5.55 ± 43.69 | 19.67 ± 46.47 |
| AM: Change at Week 8 | 7.42 ± 49.30 | 25.70 ± 58.52 | 12.22 ± 50.50 | 23.18 ± 52.65 |
| AM: Change at Week 12 | 9.85 ± 50.40 | 27.81 ± 65.30 | 14.23 ± 56.18 | 25.88 ± 57.09 |
| AM: Change at Week 24 | 5.55 ± 53.27 | 28.71 ± 69.64 | 15.43 ± 60.83 | 23.74 ± 63.71 |
| AM: Change at Week 36 | 3.24 ± 61.68 | 31.19 ± 71.59 | 12.57 ± 61.88 | 23.93 ± 65.04 |
| AM: Change at Week 52 | 2.85 ± 64.60 | 29.86 ± 75.44 | 10.99 ± 64.68 | 26.67 ± 71.63 |
| PM: Change at Week 2 | 3.33 ± 36.81 | 13.80 ± 40.59 | 3.87 ± 33.98 | 11.35 ± 36.10 |
| PM: Change at Week 4 | 5.01 ± 45.09 | 17.94 ± 55.30 | 2.73 ± 46.83 | 14.90 ± 47.42 |
| PM: Change at Week 8 | 2.82 ± 50.10 | 21.06 ± 61.80 | 7.68 ± 56.73 | 17.26 ± 53.37 |
| PM: Change at Week 12 | 3.24 ± 53.42 | 19.75 ± 68.14 | 8.52 ± 56.74 | 18.70 ± 55.60 |
| PM: Change at Week 24 | -4.89 ± 55.07 | 19.95 ± 71.50 | 7.56 ± 63.25 | 15.82 ± 61.91 |
| PM: Change at Week 36 | -6.75 ± 62.44 | 21.79 ± 75.00 | 2.64 ± 65.21 | 14.35 ± 64.66 |
| PM: Change at Week 52 | -6.43 ± 62.82 | 18.77 ± 77.37 | 2.83 ± 67.01 | 15.58 ± 72.51 |
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | 0.08 ± 0.42 | 0.23 ± 0.44 | 0.10 ± 0.37 | 0.25 ± 0.46 |
| Change at Week 4 | 0.12 ± 0.39 | 0.26 ± 0.45 | 0.12 ± 0.38 | 0.27 ± 0.47 |
| Change at Week 8 | 0.13 ± 0.41 | 0.28 ± 0.45 | 0.18 ± 0.42 | 0.29 ± 0.50 |
| Change at Week 12 | 0.13 ± 0.41 | 0.29 ± 0.49 | 0.18 ± 0.44 | 0.29 ± 0.51 |
| Change at Week 24 | 0.11 ± 0.45 | 0.29 ± 0.48 | 0.18 ± 0.46 | 0.29 ± 0.51 |
| Change at Week 36 | 0.11 ± 0.45 | 0.30 ± 0.52 | 0.19 ± 0.47 | 0.31 ± 0.52 |
| Change at Week 52 | 0.08 ± 0.45 | 0.29 ± 0.53 | 0.18 ± 0.45 | 0.31 ± 0.50 |
FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.
| liters/sec | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | 0.09 ± 0.40 | 0.22 ± 0.47 | 0.11 ± 0.44 | 0.27 ± 0.48 |
| Change at Week 4 | 0.16 ± 0.45 | 0.24 ± 0.48 | 0.15 ± 0.44 | 0.29 ± 0.48 |
| Change at Week 8 | 0.18 ± 0.45 | 0.29 ± 0.52 | 0.20 ± 0.49 | 0.32 ± 0.51 |
| Change at Week 12 | 0.18 ± 0.46 | 0.30 ± 0.53 | 0.19 ± 0.50 | 0.35 ± 0.53 |
| Change at Week 24 | 0.17 ± 0.47 | 0.34 ± 0.57 | 0.22 ± 0.56 | 0.35 ± 0.54 |
| Change at Week 36 | 0.18 ± 0.49 | 0.35 ± 0.59 | 0.22 ± 0.49 | 0.36 ± 0.56 |
| Change at Week 52 | 0.16 ± 0.50 | 0.36 ± 0.63 | 0.24 ± 0.55 | 0.36 ± 0.55 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
| liter | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | -0.07 ± 0.31 | 0.10 ± 0.37 | -0.04 ± 0.33 | 0.09 ± 0.34 |
| Change at Week 4 | -0.02 ± 0.31 | 0.10 ± 0.39 | -0.04 ± 0.36 | 0.10 ± 0.36 |
| Change at Week 8 | -0.02 ± 0.31 | 0.12 ± 0.40 | 0.03 ± 0.35 | 0.11 ± 0.37 |
| Change at Week 12 | -0.02 ± 0.33 | 0.12 ± 0.40 | 0.01 ± 0.35 | 0.11 ± 0.38 |
| Change at Week 24 | -0.05 ± 0.36 | 0.13 ± 0.43 | -0.01 ± 0.40 | 0.10 ± 0.39 |
| Change at Week 36 | -0.03 ± 0.34 | 0.12 ± 0.44 | 0.01 ± 0.38 | 0.11 ± 0.39 |
| Change at Week 52 | -0.08 ± 0.38 | 0.12 ± 0.44 | -0.02 ± 0.39 | 0.11 ± 0.40 |
LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
| LOAC per participant-year | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population | 2.972 (2.573 to 3.432) | 1.853 (1.654 to 2.076) | 2.965 (2.572 to 3.420) | 1.740 (1.554 to 1.947) |
The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.
| probability of severe exacerbation | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Probability at Week 12 | 0.165 (0.127 to 0.209) | 0.094 (0.073 to 0.119) | 0.193 (0.152 to 0.238) | 0.137 (0.112 to 0.166) |
| Probability at Week 24 | 0.275 (0.227 to 0.326) | 0.177 (0.148 to 0.208) | 0.297 (0.247 to 0.347) | 0.211 (0.180 to 0.243) |
| Probability at Week 36 | 0.364 (0.311 to 0.418) | 0.235 (0.203 to 0.270) | 0.376 (0.322 to 0.428) | 0.268 (0.234 to 0.303) |
| Probability at Week 52 | 0.434 (0.378 to 0.489) | 0.295 (0.259 to 0.331) | 0.437 (0.382 to 0.491) | 0.325 (0.288 to 0.362) |
The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.
| days | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population | 110.0 (84.00 to 144.00) | 230.0 (187.00 to 276.00) | 102.0 (74.00 to 130.00) | 264.0 (207.00 to 319.00) |
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | -0.52 ± 0.85 | -0.88 ± 0.91 | -0.58 ± 0.97 | -0.89 ± 0.94 |
| Change at Week 4 | -0.76 ± 0.90 | -1.07 ± 0.98 | -0.77 ± 1.01 | -1.06 ± 1.01 |
| Change at Week 8 | -0.94 ± 0.96 | -1.26 ± 1.03 | -1.05 ± 1.04 | -1.24 ± 1.06 |
| Change at Week 12 | -0.98 ± 1.00 | -1.33 ± 1.03 | -1.09 ± 1.09 | -1.35 ± 1.06 |
| Change at Week 36 | -1.21 ± 1.01 | -1.50 ± 1.14 | -1.22 ± 1.09 | -1.52 ± 1.09 |
| Change at Week 52 | -1.07 ± 1.08 | -1.50 ± 1.05 | -1.25 ± 1.05 | -1.50 ± 1.08 |
The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | -0.46 ± 0.70 | -0.79 ± 0.77 | -0.50 ± 0.80 | -0.82 ± 0.81 |
| Change at Week 4 | -0.65 ± 0.76 | -0.94 ± 0.85 | -0.65 ± 0.85 | -0.97 ± 0.87 |
| Change at Week 8 | -0.81 ± 0.80 | -1.11 ± 0.90 | -0.90 ± 0.89 | -1.12 ± 0.92 |
| Change at Week 12 | -0.85 ± 0.83 | -1.17 ± 0.90 | -0.92 ± 0.93 | -1.20 ± 0.92 |
| Change at Week 24 | -0.89 ± 0.91 | -1.25 ± 0.92 | -1.01 ± 0.96 | -1.22 ± 0.96 |
| Change at Week 36 | -1.04 ± 0.84 | -1.32 ± 1.01 | -1.05 ± 0.94 | -1.35 ± 0.95 |
| Change at Week 52 | -0.91 ± 0.92 | -1.32 ± 0.91 | -1.07 ± 0.91 | -1.34 ± 0.93 |
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | -0.07 ± 0.43 | -0.18 ± 0.49 | -0.09 ± 0.49 | -0.15 ± 0.50 |
| Change at Week 4 | -0.16 ± 0.59 | -0.26 ± 0.59 | -0.16 ± 0.61 | -0.27 ± 0.64 |
| Change at Week 8 | -0.26 ± 0.64 | -0.40 ± 0.68 | -0.25 ± 0.62 | -0.37 ± 0.70 |
| Change at Week 12 | -0.30 ± 0.64 | -0.45 ± 0.71 | -0.30 ± 0.69 | -0.44 ± 0.72 |
| Change at Week 24 | -0.35 ± 0.69 | -0.52 ± 0.76 | -0.36 ± 0.73 | -0.50 ± 0.73 |
| Change at Week 36 | -0.38 ± 0.69 | -0.54 ± 0.81 | -0.38 ± 0.76 | -0.56 ± 0.77 |
| Change at Week 52 | -0.41 ± 0.71 | -0.55 ± 0.84 | -0.41 ± 0.78 | -0.60 ± 0.79 |
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | -0.05 ± 0.45 | -0.17 ± 0.48 | -0.06 ± 0.45 | -0.16 ± 0.52 |
| Change at Week 4 | -0.11 ± 0.59 | -0.27 ± 0.61 | -0.14 ± 0.58 | -0.29 ± 0.64 |
| Change at Week 8 | -0.24 ± 0.64 | -0.41 ± 0.70 | -0.22 ± 0.63 | -0.40 ± 0.70 |
| Change at Week 12 | -0.26 ± 0.66 | -0.45 ± 0.72 | -0.30 ± 0.68 | -0.46 ± 0.73 |
| Change at Week 24 | -0.33 ± 0.72 | -0.52 ± 0.78 | -0.36 ± 0.72 | -0.52 ± 0.73 |
| Change at Week 36 | -0.39 ± 0.73 | -0.56 ± 0.81 | -0.39 ± 0.75 | -0.56 ± 0.80 |
| Change at Week 52 | -0.41 ± 0.74 | -0.57 ± 0.84 | -0.42 ± 0.75 | -0.61 ± 0.78 |
Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.
| number of nocturnal awakenings/night | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | -0.06 ± 0.49 | -0.15 ± 0.55 | -0.04 ± 0.62 | -0.11 ± 0.67 |
| Change at Week 4 | -0.10 ± 0.61 | -0.19 ± 0.66 | -0.11 ± 0.70 | -0.20 ± 0.67 |
| Change at Week 8 | -0.18 ± 0.65 | -0.29 ± 0.72 | -0.17 ± 0.62 | -0.24 ± 0.72 |
| Change at Week 12 | -0.21 ± 0.66 | -0.33 ± 0.75 | -0.18 ± 0.67 | -0.28 ± 0.73 |
| Change at Week 24 | -0.23 ± 0.78 | -0.36 ± 0.81 | -0.26 ± 0.65 | -0.30 ± 0.73 |
| Change at Week 36 | -0.25 ± 0.74 | -0.34 ± 0.81 | -0.26 ± 0.71 | -0.36 ± 0.74 |
| Change at Week 52 | -0.24 ± 0.69 | -0.35 ± 0.88 | -0.26 ± 0.74 | -0.41 ± 0.78 |
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.
| Number of puffs of reliever medication | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 2 | -0.21 ± 1.55 | -0.56 ± 1.96 | -0.10 ± 1.71 | -0.47 ± 1.91 |
| Change at Week 4 | -0.26 ± 2.19 | -0.68 ± 2.61 | -0.34 ± 3.42 | -0.73 ± 2.42 |
| Change at Week 8 | -0.50 ± 2.23 | -1.02 ± 2.86 | -0.65 ± 2.96 | -0.94 ± 2.86 |
| Change at Week 12 | -0.52 ± 2.28 | -1.23 ± 3.03 | -0.89 ± 3.06 | -1.08 ± 2.72 |
| Change at Week 24 | -0.77 ± 2.60 | -1.27 ± 3.05 | -0.99 ± 3.21 | -1.15 ± 2.83 |
| Change at Week 36 | -0.99 ± 2.49 | -1.30 ± 2.99 | -1.06 ± 3.57 | -1.23 ± 3.01 |
| Change at Week 52 | -0.90 ± 2.58 | -1.45 ± 3.33 | -1.12 ± 3.64 | -1.39 ± 2.97 |
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 12 | 0.90 ± 0.97 | 1.09 ± 1.03 | 0.94 ± 1.01 | 1.09 ± 1.09 |
| Change at Week 36 | 1.05 ± 1.08 | 1.26 ± 1.17 | 1.08 ± 1.16 | 1.33 ± 1.15 |
| Change at Week 52 | 1.00 ± 1.12 | 1.28 ± 1.16 | 1.02 ± 1.10 | 1.34 ± 1.16 |
EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Single Index: Change at Week 12 | 0.07 ± 0.17 | 0.09 ± 0.18 | 0.08 ± 0.18 | 0.09 ± 0.18 |
| Single Index: Change at Week 24 | 0.07 ± 0.17 | 0.09 ± 0.17 | 0.08 ± 0.18 | 0.08 ± 0.20 |
| Single Index: Change at Week 36 | 0.08 ± 0.19 | 0.09 ± 0.20 | 0.10 ± 0.18 | 0.09 ± 0.20 |
| Single Index: Change at Week 52 | 0.07 ± 0.20 | 0.10 ± 0.19 | 0.08 ± 0.19 | 0.10 ± 0.20 |
| VAS Score: Change at Week 12 | 7.69 ± 17.43 | 11.10 ± 18.90 | 6.39 ± 20.42 | 9.80 ± 19.56 |
| VAS Score: Change at Week 24 | 8.33 ± 17.58 | 11.44 ± 18.48 | 8.59 ± 20.37 | 9.21 ± 19.61 |
| VAS Score: Change at Week 36 | 9.70 ± 18.24 | 11.61 ± 19.09 | 9.31 ± 20.09 | 11.41 ± 19.40 |
| VAS Score: Change at Week 52 | 8.35 ± 18.51 | 12.98 ± 18.71 | 9.52 ± 20.81 | 11.90 ± 19.60 |
The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 12 | -2.11 ± 5.29 | -1.91 ± 5.65 | -1.55 ± 6.11 | -1.98 ± 5.89 |
| Change at Week 24 | -2.17 ± 5.71 | -1.93 ± 5.97 | -1.73 ± 6.36 | -1.88 ± 6.39 |
| Change at Week 36 | -2.52 ± 5.89 | -2.02 ± 6.34 | -2.67 ± 6.80 | -2.13 ± 6.67 |
| Change at Week 52 | -2.00 ± 6.29 | -2.36 ± 6.28 | -1.86 ± 6.79 | -2.17 ± 7.04 |
The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 12 | -6.82 ± 17.19 | -13.55 ± 16.85 | -11.30 ± 16.11 | -16.07 ± 20.54 |
| Change at Week 24 | -7.21 ± 17.10 | -14.68 ± 18.77 | -9.55 ± 16.04 | -17.41 ± 20.81 |
| Change at Week 36 | -6.10 ± 19.03 | -15.23 ± 18.20 | -8.51 ± 20.36 | -18.86 ± 21.34 |
| Change at Week 52 | -6.95 ± 17.10 | -15.78 ± 17.72 | -9.98 ± 18.01 | -19.81 ± 22.39 |
RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).
| scores on a scale | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Change at Week 12 | -0.50 ± 0.98 | -0.70 ± 0.99 | -0.44 ± 1.05 | -0.64 ± 1.06 |
| Change at Week 24 | -0.50 ± 0.92 | -0.73 ± 1.09 | -0.54 ± 1.10 | -0.60 ± 1.10 |
| Change at Week 36 | -0.56 ± 0.96 | -0.78 ± 1.15 | -0.58 ± 1.20 | -0.75 ± 1.12 |
| Change at Week 52 | -0.41 ± 0.97 | -0.90 ± 1.17 | -0.47 ± 1.33 | -0.76 ± 1.13 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 64) or entry in the LTS12551 open-label extension study regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (for Dupilumab 200 mg) q2w | 3/313 (1%) | 26/313 (8.3%) | 185/313 (59.1%) |
| Dupilumab 200 mg q2w | 1/631 (0.2%) | 51/631 (8.1%) | 363/631 (57.5%) |
| Placebo (for Dupilumab 300 mg) q2w | 0/321 (0%) | 28/321 (8.7%) | 197/321 (61.4%) |
| Dupilumab 300 mg q2w | 5/632 (0.8%) | 56/632 (8.9%) | 378/632 (59.8%) |
| Event | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 10/313 | 11/631 | 5/321 | 7/632 |
| PneumoniaInfections and infestations | 0/313 | 0/631 | 2/321 | 4/632 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/313 | 0/631 | 2/321 | 2/632 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/313 | 0/631 | 2/321 | 0/632 |
| Atypical pneumoniaInfections and infestations | 1/313 | 0/631 | 0/321 | 0/632 |
| Capnocytophaga infectionInfections and infestations | 1/313 | 0/631 | 0/321 | 0/632 |
| Hepatitis CInfections and infestations | 1/313 | 0/631 | 0/321 | 0/632 |
| Pyelonephritis chronicInfections and infestations | 1/313 | 0/631 | 0/321 | 0/632 |
| Anaplastic thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/313 | 0/631 | 0/321 | 0/632 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/313 | 0/631 | 1/321 | 0/632 |
| Event | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w |
|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 60/313 | 121/631 | 64/321 | 112/632 |
| Injection site erythemaGeneral disorders | 13/313 | 76/631 | 22/321 | 98/632 |
| BronchitisInfections and infestations | 47/313 | 73/631 | 43/321 | 70/632 |
| Upper respiratory tract infectionInfections and infestations | 37/313 | 70/631 | 48/321 | 77/632 |
| InfluenzaInfections and infestations | 29/313 | 36/631 | 22/321 | 38/632 |
| SinusitisInfections and infestations | 27/313 | 36/631 | 29/321 | 26/632 |
| HeadacheNervous system disorders | 26/313 | 47/631 | 25/321 | 40/632 |
| Injection site oedemaGeneral disorders | 2/313 | 23/631 | 5/321 | 40/632 |
| Urinary tract infectionInfections and infestations | 17/313 | 17/631 | 12/321 | 20/632 |
| Accidental overdoseInjury, poisoning and procedural complications | 16/313 | 31/631 | 16/321 | 34/632 |
Analysis was performed on all randomized participants.
| Age, Continuous(years) | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|---|---|
| Mean | 48.2 ± 15.6 | 47.9 ± 15.3 | 48.2 ± 14.7 | 47.7 ± 15.6 | 47.9 ± 15.3 |
| Age, Customized(Participants) | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|---|---|
| Adolescents (12-17 years) | 21 | 34 | 18 | 34 | 107 |
| Adults (18-64 years) | 253 | 512 | 263 | 516 | 1544 |
| From 65-84 years | 43 | 85 | 40 | 83 | 251 |
| Sex: Female, Male(Participants) | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|---|---|
| Female | 198 | 387 | 218 | 394 | 1197 |
| Male | 119 | 244 | 103 | 239 | 705 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 81 | 171 | 79 | 159 | 490 |
| Not Hispanic or Latino | 236 | 460 | 242 | 474 | 1412 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|---|---|
| Caucasian/White | 265 | 510 | 273 | 529 | 1577 |
| Black/of African descent | 14 | 33 | 12 | 21 | 80 |
| Asian/Oriental | 33 | 78 | 33 | 79 | 223 |
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Other | 4 | 9 | 3 | 4 | 20 |
| Blood Eosinophil Group(Participants) | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|---|---|
| <0.15 Giga/L | 85 | 193 | 83 | 181 | 542 |
| >=0.15 - <0.3 Giga/L | 84 | 173 | 95 | 175 | 527 |
| >=0.3 Giga/L | 148 | 264 | 142 | 277 | 831 |
| ICS Dose Level(Participants) | Placebo (for Dupilumab 200 mg) q2w | Dupilumab 200 mg q2w | Placebo (for Dupilumab 300 mg) q2w | Dupilumab 300 mg q2w | Total |
|---|---|---|---|---|---|
| High | 172 | 317 | 167 | 323 | 979 |
| Medium | 144 | 310 | 151 | 303 | 908 |
| Low | 1 | 4 | 3 | 7 | 15 |
Showing the first 100 of 389 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Apr 2015, a primary completion of Jul 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab